Albany Molecular Research Earnings: Here’s Why the Stock is Spiking Now

Albany Molecular Research Inc. (NASDAQ:AMRI) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 15%.

Albany Molecular Research Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $0.17 in the quarter versus EPS of $-0.19 in the year-earlier quarter.

Revenue: Rose 44.24% to $67.2 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Albany Molecular Research Inc. reported adjusted EPS income of $0.17 per share. By that measure, the company beat the mean analyst estimate of $0.09. It beat the average revenue estimate of $56.49 million.

Quoting Management: AMRI Chairman, President and CEO Thomas E. D’Ambra said, “We are pleased to report fourth quarter and full year results for 2012, which reflect operating improvements largely driven by the record performance in our Large Scale Manufacturing business. In addition, a number of actions taken in prior periods are demonstrating a positive impact on our bottom line. Our overall performance for fiscal year 2012 demonstrates the consistent and positive direction our company is moving as we continue to position and integrate our global facilities and high quality services. Although discovery and early development demand continues to be soft relative to prior periods, we have also delivered progress and entered into new relationships that hold promise for future growth. We are building key long-term relationships with customers that will benefit us in 2013 and beyond. Led by the AMRI SMARTSOURCING™ strategy implemented in the first quarter of 2012, AMRI is well positioned to maintain positive momentum into 2013 and, most importantly, support and help our customers discover, develop and bring to market the exciting drugs of today and tomorrow.”

Key Stats (on next page)…

Revenue increased 20.49% from $55.77 million in the previous quarter. EPS increased to $0.17 in the quarter versus EPS of $0.00 in the previous quarter.

Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.03 and has not changed. For the current year, the average estimate is a profit of $0.17, which is the same with that ninety days ago.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]